Semaglutide: The Complete 2026 Guide

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. You'll find it under three brand names — Ozempic, Wegovy, and Rybelsus — and as a compounded medication through telehealth. This page covers what it does, who it's for, side effects, cost, and how to access it.

Last updated May 1, 2026.

Advertising disclosure: GLP Insights is reader-supported. When you book a consultation or purchase through our partner links, we may earn a commission at no additional cost to you. This does not influence which providers or medications we discuss. Learn how this site is funded.

Start Semaglutide Consultation

Licensed providers · All 50 states · No insurance required

✓ Updated monthly with FDA + clinical research ✓ Affiliate-supported, editorially independent ✓ Plain-English explanations of complex medical topics

What Is Semaglutide?

Semaglutide is a synthetic peptide that activates the GLP-1 receptor, modified to resist breakdown by DPP-4. The result is a long-acting drug taken once weekly (injection) or daily (oral). It is FDA-approved for type 2 diabetes (Ozempic, Rybelsus), chronic weight management in adults with obesity or overweight with comorbidity (Wegovy), and reducing cardiovascular events in patients with established cardiovascular disease.

Semaglutide Brand Names

Brand	Indication	Form	Max dose	Cash price
Ozempic	Type 2 diabetes	Weekly injection	2.0 mg	$950–1,050/mo
Wegovy	Weight management; CV risk	Weekly injection	2.4 mg	$1,300+/mo
Rybelsus	Type 2 diabetes	Daily oral tablet	14 mg	$950/mo
Compounded semaglutide	Off-label (per Rx)	Weekly injection (vial)	Per Rx	$199–399/mo

How Semaglutide Works

Semaglutide binds the GLP-1 receptor on multiple tissues. In the pancreas, it amplifies glucose-dependent insulin release and suppresses glucagon. In the gut, it slows gastric emptying. In the brain, it acts on the hypothalamus and brainstem to reduce appetite and food intake. The result is improved blood sugar control and significant weight loss.

Weight Loss Data: What Trials Show

The STEP-1 trial (NEJM 2021) randomized 1,961 adults with obesity to semaglutide 2.4 mg weekly or placebo for 68 weeks alongside lifestyle counseling. Mean body weight change was −14.9% in the semaglutide group versus −2.4% in placebo. Almost 70% of patients in the semaglutide group lost at least 10% of body weight.

The STEP-5 trial extended follow-up to 104 weeks and showed sustained weight loss. STEP-4 examined discontinuation and showed significant regain — about two-thirds of weight lost was regained within a year of stopping.

Diabetes Outcomes

In the SUSTAIN trials, semaglutide consistently produced HbA1c reductions of 1.4–1.8% from baseline, larger than most other glucose-lowering medications. The SUSTAIN-6 cardiovascular outcomes trial showed reduced major adverse cardiovascular events (MACE) in patients with established cardiovascular disease.

See If Semaglutide Is Right for You

Licensed providers · All 50 states · No insurance required

Dosing and Titration

Injectable semaglutide is started low and increased over months to minimize gastrointestinal side effects. The Wegovy schedule is:

Weeks 1–4: 0.25 mg weekly
Weeks 5–8: 0.5 mg weekly
Weeks 9–12: 1.0 mg weekly
Weeks 13–16: 1.7 mg weekly
Week 17+: 2.4 mg weekly (maintenance)

Some patients tolerate slower titration; others stay at lower maintenance doses if they hit their goals.

Side Effects of Semaglutide

Most common: nausea, diarrhea, vomiting, constipation, abdominal pain, fatigue, headache. Most are mild to moderate and resolve in weeks. Serious but uncommon: pancreatitis, gallbladder events, severe hypoglycemia (with insulin or sulfonylureas), allergic reactions. FDA boxed warning covers thyroid C-cell tumors observed in rodents — semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN-2.

Read the full GLP-1 side effects guide.

Who Should Not Take Semaglutide

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia type 2 (MEN-2)
History of pancreatitis
Severe gastrointestinal disease (e.g., gastroparesis)
Pregnancy or planning pregnancy (discontinue at least 2 months before)
Children under 12 (for Wegovy; Saxenda has a pediatric indication for liraglutide)
Known hypersensitivity to semaglutide

Cost: Brand vs Compounded

Brand Wegovy: ~$1,300+/month list price; WegovyCare or savings card can reduce out-of-pocket significantly for some patients
Brand Ozempic: ~$950–1,050/month; manufacturer programs vary
Brand Rybelsus: ~$950/month
Compounded semaglutide via telehealth: $199–399/month

Full pricing on GLP-1 cost.

How to Get Semaglutide Prescribed

Online telehealth: video consult, prescription, ships in 7–10 business days for compounded; or sent to local pharmacy for brand
Primary care doctor: standard prescription pathway, often with prior authorization for insurance
Obesity medicine specialist: specialized providers for complex cases

Frequently Asked Questions

What is semaglutide? +

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It is sold as Ozempic and Rybelsus (for type 2 diabetes) and Wegovy (for weight management and cardiovascular risk reduction).

Is there a generic for semaglutide? +

No FDA-approved generic exists. Compounded semaglutide produced by licensed compounding pharmacies is currently available through telehealth, generally tied to FDA shortage status.

What is the difference between Ozempic and Wegovy? +

Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes at doses up to 2.0 mg weekly. Wegovy is FDA-approved for weight management at doses up to 2.4 mg weekly.

Can semaglutide cause weight loss without diabetes? +

Yes. Wegovy was specifically FDA-approved for weight management in adults with BMI 30+ or 27+ with comorbidity. The STEP-1 trial showed about 15% average body weight reduction at 68 weeks.

How long do I need to take semaglutide? +

Most patients require ongoing treatment. Clinical data show significant weight regain after stopping. Treatment duration should be discussed with your provider.

Sources

Wilding et al. STEP-1. N Engl J Med 2021. DOI
Marso et al. SUSTAIN-6. N Engl J Med 2016.
FDA prescribing information for Ozempic, Wegovy, Rybelsus.